Rigel Pharmaceuticals, Inc. (RIGL)
| Market Cap | 868.24M +21.8% |
| Revenue (ttm) | 276.79M +3.3% |
| Net Income | 321.91M +229.1% |
| EPS | 16.45 +202.7% |
| Shares Out | 18.68M |
| PE Ratio | 2.83 |
| Forward PE | 14.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 246,110 |
| Open | 46.46 |
| Previous Close | 46.86 |
| Day's Range | 45.68 - 46.79 |
| 52-Week Range | 24.95 - 52.24 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 63.00 (+35.54%) |
| Earnings Date | Aug 4, 2026 |
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test;... [Read more]
Financial Performance
In 2025, Rigel Pharmaceuticals's revenue was $294.28 million, an increase of 64.15% compared to the previous year's $179.28 million. Earnings were $367.02 million, an increase of 1999.08%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price target is $63.0, which is an increase of 35.54% from the latest price.
News
Rigel Pharmaceuticals price target raised to $49 from $40 at Piper Sandler
Piper Sandler raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $49 from $40 on a solid quarter, layering in Veppanu. The firm keeps a Neutral rating on the…
Rigel Pharmaceuticals’ Veppanu available for metastatic breast cancer
Rigel Pharmaceuticals (RIGL) announced Veppanu – vepdegestrant – is now available by prescription in the U.S. for the treatment of adults with estrogen receptor-positive/human epidermal growth factor ...
Rigel Pharmaceuticals price target raised to $85 from $57 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $85 from $57 and keeps a Buy rating on the shares after the company announced…
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif.,...
Rigel Pharmaceuticals price target raised to $83 from $81 at Citi
Citi raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $83 from $81 and keeps a Buy rating on the shares. The firm says the company’s Q2 report support…
Rigel Pharmaceuticals raises FY26 revenue view to $285M-$295M from $275M-$290M
Consensus is for FY26 revenue $278.89M. Sees FY26 net product sales $255M-$265M; and contract revenues $30M, an increase from the prior range of approximately $20M-$25M.
Rigel Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth, record sales for TAVALISSE, and the addition of VEPPANU, a first-in-class PROTAC for metastatic breast cancer, to the portfolio. Guidance was raised, with VEPPANU expected to drive future growth and R289 advancing in lower-risk MDS.
Rigel Pharmaceuticals Earnings release: Q2 2026
Rigel Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Rigel Pharmaceuticals Quarterly report: Q2 2026
Rigel Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
Rigel Pharmaceuticals Slides: Q2 2026
Rigel Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Rigel Pharmaceuticals reports Q2 EPS 88c, consensus (8c)
Reports Q2 revenue $78.7M, consensus $55.27M. “Rigel delivered a strong Q2, highlighted by record net product sales, continued profitability and the in-license of VEPPANU, the first and only FDA-appro...
Rigel Reports Second Quarter 2026 Financial Results
Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and net income of $17.3 million Expanded c...
Rigel Pharmaceuticals Slides: Corporate presentation
Rigel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close o...
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. In...
Rigel appoints Alison Hannah as Chief Medical Officer and Vice President
Rigel Pharmaceuticals (RIGL) announced the appointment of Alison L. Hannah, to the role of Executive Vice President and Chief Medical Officer. Hannah has resigned from Rigel’s Board of Directors, effe...
Rigel Appoints Board Member Alison L. Hannah, M.D.
Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN FR...
Rigel closes license agreement for Veppanu
Rigel Pharmaceuticals (RIGL) announced the closing of its license agreement for VEPPANU, or vepdegestrant, following the early termination of the waiting period under the Hart-Scott Rodino Antitrust I...
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today annou...
Rigel Pharmaceuticals Slides: Corporate presentation
Rigel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
Rigel Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company outlined a transformational growth strategy, highlighted by the upcoming launch of VEPPANU, a first-in-class PROTAC for metastatic breast cancer, and strong commercial performance from its existing portfolio. R289 for lower-risk MDS shows promising early results, and financial discipline supports continued expansion.
Rigel to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announ...
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO ® (pralsetinib) as first-line treatment in patients with RET fusion-positive NS...
Rigel Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
A four-pillar growth strategy has driven strong revenue and product expansion, highlighted by the in-licensing of VEPPANU, a first-in-class PROTAC for metastatic breast cancer. Profitability was achieved in Q3 2024, with further growth expected from new launches and pipeline advancements.
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announ...